Publications by authors named "Lynn C Lunsonga"

Article Synopsis
  • Sodium/glucose cotransporter 2 inhibitors (SGLT2is), such as empagliflozin, show potential heart protection benefits in individuals with or without diabetes and can inhibit a key cardiac sodium current linked to congenital long QT syndrome type 3 (LQT3).
  • Researchers used the whole-cell patch-clamp technique to study how empagliflozin affects late sodium current (late I) in various LQT3 mutations of the Nav1.5 channel.
  • Empagliflozin specifically inhibited late I in certain mutations without altering channel kinetics, suggesting it could be an effective targeted treatment for patients with LQT3 mutations in the inactivation gate area.
View Article and Find Full Text PDF